China’s Henlius Biotech prices Hong Kong IPO at bottom end of range – sources
Shanghai Henlius Biotech
has raised $410 million after pricing its Hong Kong
initial public offering at the bottom end of the indicative
pricing range, two people with direct knowledge of the matter
said on Wednesday.
has raised $410 million after pricing its Hong Kong
initial public offering at the bottom end of the indicative
pricing range, two people with direct knowledge of the matter
said on Wednesday.
Posted by Reuters
